Corcept Therapeutics (CORT) AI Stock Analysis

• Market Cap: $7.70B
• Dividend Yield: N/A
• Average Volume (3M): 2.04M
• Price to Earnings (P/E): 54.9
• Beta (1Y): 0.25
• Revenue Growth: 39.94%
• EPS Growth: 32.10%
• Country: US
• Employees: 500
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): 1.23
• Shares Outstanding: 105,503,430
• 10 Day Avg. Volume: 3,700,927
• 30 Day Avg. Volume: 2,039,227
• PEG Ratio: 1.71
• Price to Book (P/B): N/A
• Price to Sales (P/S): 9.17
• Price to Cash Flow (P/CF): 26.10
• P/FCF Ratio: 26.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $137.60
• Price Target Upside: 100.52% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

Corcept Therapeutics scores well due to its strong financial performance and positive technical indicators. While the valuation is a concern due to its high P/E ratio, the earnings call reveals a strong growth outlook, supported by substantial cash reserves and advancements in its drug pipeline. The legal challenges and operational issues are minor setbacks in an otherwise strong profile.

Positive Factors

Clinical Trials

Relacorilant achieves strong progression-free survival (PFS) and overall survival (OS) in ovarian cancer.

Financial Performance

FY25 revenue guidance of $900-950M represents a 33.5% year-over-year growth.

Market Potential

Relacorilant could potentially receive a broader label than Elahere as it is not limited to FRα-positive patients.

Negative Factors

Competition

The data presented showed similar overall survival outcomes between Elahere and relacorilant, suggesting competitive efficacy.

Past Financial Anomalies

Korlym's 4Q24 was an anomaly, focus on guidance.

Regulatory Dependency

Corcept can file an NDA based on either PFS or OS results from the ROSELLA trial, providing flexibility in regulatory submissions.

Corcept Therapeutics Business Overview & Revenue Model

Company Description

Corcept Therapeutics (CORT) is a pharmaceutical company specializing in the development and commercialization of drugs that modulate the effects of cortisol. The company's primary focus is on developing treatments for severe metabolic, oncologic, and psychiatric disorders. Its flagship product, Korlym, is approved for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome.

How the Company Makes Money

Corcept Therapeutics generates revenue primarily through the sales of its FDA-approved medication, Korlym. The company targets patients with Cushing's syndrome, a condition characterized by excessive cortisol levels, providing a niche market for its product. Revenue is generated through direct sales to specialty pharmacies and distributors that supply healthcare providers and patients. Additionally, the company invests in research and development to expand its product offerings and potentially introduce new medications to market, which could diversify and increase its revenue streams in the future. Corcept's partnerships with research institutions and healthcare organizations also contribute to its development pipeline, although these are not primary revenue sources.

Corcept Therapeutics Financial Statement Overview

Summary

Corcept Therapeutics presents a robust financial profile with strong profitability, a solid balance sheet, and efficient cash flow management. The company demonstrates consistent revenue growth, high gross profit margins, low leverage risk, and impressive return on equity. While cash flow variability exists, the overall financial health is strong.

Income Statement

Corcept Therapeutics demonstrates strong profitability with a consistent revenue growth trend. Over the years, their gross profit margin remains high, indicating efficient cost management. The net profit margin has improved, showcasing enhanced profitability. The revenue growth rate is robust, reflecting a successful business expansion and market presence. EBIT and EBITDA margins are stable, further indicating healthy operational efficiency.

Balance Sheet

The company maintains a strong balance sheet with a low debt-to-equity ratio, indicating minimal leverage risk. Return on Equity (ROE) is impressive, reflecting effective management of shareholder funds. The equity ratio is high, signifying strong balance sheet stability. Overall, the firm is well-capitalized with a solid equity base and low liabilities.

Cash Flow

Corcept Therapeutics displays consistent positive cash flow from operations, supporting its free cash flow growth. The operating cash flow to net income ratio is healthy, demonstrating a strong conversion of income to cash. The free cash flow to net income ratio also reflects efficient cash management, although there is some variability in cash flow from financing and investing activities.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
675.04M	482.38M	401.86M	365.98M	353.87M
	Gross Profit
664.16M	475.89M	396.47M	360.70M	348.29M
	EBIT
136.95M	107.28M	112.63M	124.48M	128.20M
	EBITDA
136.95M	108.32M	112.63M	124.48M	130.44M
	Net Income Common Stockholders
139.73M	106.14M	101.42M	112.51M	106.01M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
383.33M	368.22M	436.62M	335.81M	476.89M
	Total Assets
840.55M	621.52M	583.43M	423.76M	571.73M
	Total Debt
6.94M	151.00K	1.14M	526.00K	2.55M
	Net Debt
-120.73M	-135.40M	-435.48M	-335.29M	-474.34M
	Total Liabilities
160.96M	114.81M	81.59M	47.95M	48.39M
	Stockholders Equity
679.59M	506.70M	501.84M	375.81M	523.34M
Cash Flow		Free Cash Flow
195.90M	126.90M	119.91M	167.42M	150.73M
	Operating Cash Flow
198.07M	127.04M	120.32M	167.89M	151.97M
	Investing Cash Flow
-177.60M	90.91M	-114.33M	136.13M	-119.26M
	Financing Cash Flow
-28.35M	-148.72M	-17.28M	-302.59M	12.21M

Corcept Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 68.62
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CORT, the sentiment is Neutral. The current price of 68.62 is below the 20-day moving average (MA) of 68.65, above the 50-day MA of 65.39, and above the 200-day MA of 50.30, indicating a neutral trend. The MACD of 5.26 indicates Negative momentum. The RSI at 65.84 is Neutral, neither overbought nor oversold. The STOCH value of 55.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CORT.

Corcept Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HALO	79 Outperform	$7.49B	16.81	198.42%	―	22.44%	63.47%
CORT	78 Outperform	$7.70B	54.93	23.55%	―	39.94%	32.10%
TECH	66 Neutral	$7.79B	50.07	7.82%	0.65%	4.46%	-29.62%
SRPT	66 Neutral	$5.40B	21.11	19.71%	―	52.97%	―
LEGN	57 Neutral	$5.74B	―	-15.45%	―	119.97%	67.21%
MDGL	54 Neutral	$6.79B	―	-80.35%	―	―	-10.89%
Sector *	48 Neutral	$6.25B	1.14	-46.26%	2.69%	19.24%	1.75%

Corcept Therapeutics Corporate Events

Corcept Therapeutics Reports Strong 2024 Financial Results

On February 26, 2025, Corcept Therapeutics announced its financial results for the fourth quarter and full year 2024, reporting a 40% increase in revenue to $675 million and a 33% rise in net income to $141.2 million compared to 2023. The company highlighted significant progress in its clinical development programs, including the submission of a New Drug Application for relacorilant for hypercortisolism and promising results from various studies, positioning relacorilant as a potential new standard of care. The announcement underscores Corcept’s strong financial performance and strategic advancements in its clinical pipeline, which could enhance its market position and impact stakeholders positively.